Penetration of clarithromycin in experimental pleural empyema model fluid

被引:16
作者
Liapakis, IE
Light, RW
Pitiakoudis, MS
Karayiannakis, AJ
Giamarellos-Bourboulis, EJ
Ismailos, G
Anagnostoulis, S
Simopoulos, CE
Bouros, DE
机构
[1] Democritus Univ Thrace, Sch Med, Dept Pneumol, Alexandroupolis, Greece
[2] Democritus Univ Thrace, Sch Med, Dept Surg 2, Alexandroupolis, Greece
[3] St Thomas Hosp, Dept Pulm, Nashville, TN USA
[4] Vanderbilt Univ, Nashville, TN USA
[5] Elpen SA Pharmaceut, Athens, Greece
[6] Univ Gen Hosp Attikon, Dept Internal Med 4, Athens, Greece
关键词
clarithromycin; turpentine; Escherichia coli; pleural empyema; experimental; antibiotics; pleural infection; pleural effusion;
D O I
10.1159/000085371
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The degree of penetration of clarithromycin into the pleural fluid has not been studied. Objective: To determine the degree to which clarithromycin penetrates into empyemic pleural fluid using a new rabbit model of empyema. Methods: An empyema was created via the intrapleural injection of 1 ml turpentine followed 24 h later by instillation of 5 ml ( 1010) Escherichia coli bacteria ( ATCC 35218) into the pleural space of New Zealand white rabbits. After an empyema was verified by thoracentesis and pleural fluid analysis, clarithromycin 30 mg/ kg was administered intravenously. Antibiotic levels were determined on samples of pleural fluid and blood samples collected serially over 12 h. Antibiotic levels were estimated using HPLC. Results: The antibiotic penetrated well into the empyemic pleural fluid (AUC(PF)/ AUC(serum) ratio of 1.57). The time to equilibration between the pleural fluid and blood antibiotic levels was 8 h. The peak pleural fluid level ( Cmax(PF) of 2.88 mu g/ml) occurred 1 h (Tmax(PF) of 1 h) after infusion and decreased thereafter. The Cmax(serum) was 3.53 mu g/ml at 1 h after administration. Conclusion: The levels of clarithromycin in the pleural fluid after intravenous administration are inhibitory for most of the usual pathogens causing empyema. The degree of penetration of clarithromycin should be considered when macrolides are selected for the treatment of patients with empyema. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:296 / 300
页数:5
相关论文
共 23 条
[1]   Polymorphonuclear elastase in the early diagnosis of complicated pyogenic pleural effusions [J].
Alemán, C ;
Alegre, J ;
Segura, RM ;
Armadans, L ;
Suriñach, JM ;
Varela, E ;
Soriano, T ;
Recio, J ;
de Sevilla, TF .
RESPIRATION, 2003, 70 (05) :462-467
[2]   Pleural interleukin-1β in differentiating transudates and exudates:: Comparative analysis with other biochemical parameters [J].
Alexandrakis, MG ;
Kyriakou, D ;
Alexandraki, R ;
Pappa, KA ;
Antonakis, N ;
Bouros, D .
RESPIRATION, 2002, 69 (03) :201-206
[3]  
[Anonymous], EUR RESP MON
[4]  
Bouros D, 1999, Monaldi Arch Chest Dis, V54, P258
[5]   Comparison of the use and accuracy of methods for determining pleural fluid pH [J].
Chandler, TH ;
McCoskey, EH ;
Byrd, RP ;
Roy, TM .
SOUTHERN MEDICAL JOURNAL, 1999, 92 (02) :214-217
[6]  
Drusano GL, 1997, J CHEMOTHERAPY, V9, P38
[7]   Repeated thoracentesis:: An important risk factor for eosinophilic pleural effusion? [J].
García, MAM ;
Viedma, EC ;
Tordera, MP ;
Sanchis-Aldás, JL .
RESPIRATION, 2003, 70 (01) :82-86
[8]   Penetration of newer quinolones n the empyema fluid [J].
Liapakis, IE ;
Kottakis, I ;
Tzatzarakis, MN ;
Tsatsakis, AM ;
Pitiakoudis, MS ;
Ypsilantis, P ;
Light, RW ;
Simopoulos, CE ;
Bouros, DE .
EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (03) :466-470
[9]  
LIAPAKIS IE, 2004, PLEURAL DIS, P999
[10]  
Light R. W., 1995, PLEURAL DIS, P1